We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

31 hedge funds and large institutions have $14.9M invested in Protara Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.44% less ownership

Funds ownership: 52.69% → 50.25% (-2.4%)

6% less funds holding

Funds holding: 33 → 31 (-2)

6% less capital invested

Capital invested by funds: $16M → $14.9M (-$1.02M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

77% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 13

Holders
31
Holders Change
-2
Holders Change %
-6.06%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
3
Reduced
13
Closed
4
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
PFMU
Privium Fund Management (UK)
United Kingdom
+$119K
2
Renaissance Technologies
Renaissance Technologies
New York
+$84.7K
3
OM
Opaleye Management
Massachusetts
+$81K
4
FAIM
Financial Advocates Investment Management
Washington
+$21K
5
VF
Virtu Financial
New York
+$8K

Top Sellers

Rank Fund Capital Flow
1
DAM
DLD Asset Management
New York
-$461K
2
Citadel Advisors
Citadel Advisors
Florida
-$244K
3
IC
Ikarian Capital
Texas
-$234K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$47K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$43.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$7.99M +$81K +23,900 +0.9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.26M -$54 -16 -0%
PA
3
Perceptive Advisors
New York
$859K – – –
FAIM
4
Financial Advocates Investment Management
Washington
$678K +$21K +6,187 New
BC
5
Boxer Capital
California
$619K – – –
BBA
6
Baker Bros. Advisors
New York
$591K – – –
IC
7
Ikarian Capital
Texas
$558K -$234K -69,189 -27%
Citadel Advisors
8
Citadel Advisors
Florida
$505K -$244K -72,049 -30%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$247K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$234K +$84.7K +25,000 +46%
BCM
11
Bridgeway Capital Management
Texas
$189K – – –
Assenagon Asset Management
12
Assenagon Asset Management
Luxembourg
$173K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$155K -$2.37K -700 -1%
Two Sigma Investments
14
Two Sigma Investments
New York
$151K -$8.47K -2,500 -5%
Millennium Management
15
Millennium Management
New York
$149K -$35.8K -10,577 -17%
BlackRock
16
BlackRock
New York
$105K -$10.2K -3,007 -8%
PFMU
17
Privium Fund Management (UK)
United Kingdom
$104K +$119K +35,000 New
State Street
18
State Street
Massachusetts
$91K – – –
Northern Trust
19
Northern Trust
Illinois
$59K – – –
BFM
20
Boothbay Fund Management
New York
$56K -$23.1K -6,802 -27%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$53K – – –
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$47K -$43.8K -12,918 -45%
VF
23
Virtu Financial
New York
$37K +$8K +2,362 +23%
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$18K – – –
O
25
OrbiMed
New York
$2.46K – – –
1
2

TARA Hedge Fund Activity: Q3 2022 in Review

31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2022, worth a combined $14.9M — down 6.4% from $16M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of TARA and 2 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 3 added.

The largest buyer was Privium Fund Management (UK), opening a new position worth an estimated $119K. The largest seller was DLD Asset Management, exiting entirely with an estimated $461K sold.

  • 31 institutional investors held Protara Therapeutics (TARA) as of Q3 2022, down from 33 in Q2 2022.
  • Funds reported $14.9M of Protara Therapeutics stock for Q3 2022, down 6.4% quarter-over-quarter.
  • 2 funds opened new Protara Therapeutics positions in Q3 2022 and 4 closed out, a net change of -2 holders.
  • The largest Protara Therapeutics buyer in Q3 2022 was Privium Fund Management (UK), an estimated $119K added.
  • The largest Protara Therapeutics seller in Q3 2022 was DLD Asset Management, an estimated $461K sold.

Based on aggregated 13F filings for Q3 2022.